公开(公告)号：WO2008084410A2

公开(公告)日：2008-07-17

申请号：PCT/IB2008001111

申请日：2008-01-03

Applicant: HUMABS LLC ,  LANZAVECCHIA ANTONIO ,  MACAGNO ANNALISA

Inventor： LANZAVECCHIA ANTONIO ,  MACAGNO ANNALISA

CPC classification number: A61K39/3955 ,  A61K39/42 ,  C07K16/088 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The antibodies of the invention also have a high potency for the neutralisation of infection. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.

Abstract translation: 本发明涉及对人巨细胞病毒特异性并以高亲和力结合的中和抗体以及产生这种抗体的永生化B细胞。 本发明的抗体还具有用于中和感染的高效力。 本发明还涉及抗体结合的表位以及筛选方法中抗体和表位的使用以及疾病的诊断和治疗。

公开(公告)号：WO2010007463A1

公开(公告)日：2010-01-21

申请号：PCT/IB2008/002683

申请日：2008-07-16

Applicant: HUMABS LLC ,  LANZAVECCIA, Antonio ,  MACAGNO, Annalisa

Inventor： LANZAVECCIA, Antonio ,  MACAGNO, Annalisa

IPC: C07K16/08 ,  G01N33/569 ,  A61K39/395

CPC classification number: C07K16/088 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56994 ,  G01N2500/04

Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus (hCMV), specifically the antibodies of the invention are specific for a combination of the hCMV proteins UL128, UL130 and UL131A. Antibodies of the invention neutralise infection with high potency. The invention also relates to immortalised B cells that produce such antibodies, to the epitope that the antibodies bind to as well as the use of the antibodies and the epitope in screening methods as well as the diagnosis and therapy of disease.

Abstract translation: 本发明涉及对人巨细胞病毒（hCMV）特异性的中和抗体，具体地说，本发明的抗体对hCMV蛋白UL128，UL130和UL131A的组合是特异性的。 本发明的抗体以高效力中和感染。 本发明还涉及产生这种抗体的永生化B细胞，抗体结合的表位以及筛选方法中抗体和表位的使用以及疾病的诊断和治疗。

公开(公告)号：WO2010007533A9

公开(公告)日：2017-08-10

申请号：PCT/IB2009006641

申请日：2009-07-15

Applicant: INST FOR RES IN BIOMEDICINE ,  LANZAVECCHIA ANTONIO ,  MACAGNO ANNALISA

Inventor： LANZAVECCHIA ANTONIO ,  MACAGNO ANNALISA

IPC: C07K16/08

CPC classification number: C07K16/088 ,  A01D34/63 ,  A01D34/71 ,  A01D2101/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2710/16122

Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

Abstract translation: 本发明涉及中和hCMV具有高效力的中和抗体及其抗体片段，其中所述抗体和抗体片段对hCMV基因UL产物中的一种或两种或更多种的组合是特异性的。 本发明还涉及产生此类抗体和抗体片段的永生化B细胞以及结合此类抗体和抗体片段的表位。 另外，本发明涉及抗体，抗体片段和表位在筛选方法以及疾病的诊断，预防和治疗中的用途。

公开(公告)号：WO2010007533A2

公开(公告)日：2010-01-21

申请号：PCT/IB2009/006641

申请日：2009-07-15

Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE ,  LANZAVECCHIA, Antonio ,  MACAGNO, Annalisa

Inventor： LANZAVECCHIA, Antonio ,  MACAGNO, Annalisa

IPC: C07K16/00

CPC classification number: C07K16/088 ,  A01D34/63 ,  A01D34/71 ,  A01D2101/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2710/16122

Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

Abstract translation: 本发明涉及中和hCMV具有高效力的中和抗体及其抗体片段，其中所述抗体和抗体片段对hCMV基因UL产物中的一种或两种或更多种的组合是特异性的 。 本发明还涉及产生此类抗体和抗体片段的永生化B细胞以及结合此类抗体和抗体片段的表位。 此外，本发明涉及抗体，抗体片段和表位在筛选方法以及疾病的诊断，预防和治疗中的用途。

公开(公告)号：WO2008084410A3

公开(公告)日：2008-07-17

申请号：PCT/IB2008/001111

申请日：2008-01-03

Applicant: HUMABS LLC ,  LANZAVECCHIA, Antonio ,  MACAGNO, Annalisa

Inventor： LANZAVECCHIA, Antonio ,  MACAGNO, Annalisa

IPC: C07K16/08 ,  C12N15/13 ,  A61K39/42 ,  A61P31/22

Abstract: Neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The antibodies also have a high potency for the neutralisation of infection. Characterization of the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.

公开(公告)号：WO2010007533A3

公开(公告)日：2010-08-12

申请号：PCT/IB2009006641

申请日：2009-07-15

Applicant: INST RESEARCH IN BIOMEDICINE ,  LANZAVECCHIA ANTONIO ,  MACAGNO ANNALISA

Inventor： LANZAVECCHIA ANTONIO ,  MACAGNO ANNALISA

IPC: C07K16/08

CPC classification number: C07K16/088 ,  A01D34/63 ,  A01D34/71 ,  A01D2101/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2710/16122

Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

Abstract translation: 本发明涉及在中和hCMV中具有高效力的中和抗体及其抗体片段，其中所述抗体和抗体片段对于一种或两种或更多种hCMV基因UL产品的组合是特异性的。 本发明还涉及产生和结合这些抗体和抗体片段的表位的永生化B细胞。 此外，本发明涉及抗体，抗体片段和表位在筛选方法以及疾病的诊断，预防和治疗中的用途。